Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics:

• Introduction (0:00)
• Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)
• Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O'Shaughnessy and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)
• Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)

CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:

• Introduction (0:00)
• Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)
• Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)

CME information and select publications